Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDYI in Males with Hypoactive Sexual Desire Disorder
NCT04002661Phase 2Terminated
- Start
- May 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of flibanserin in hypoactive sexual desire disorder (HSDD) (2 arms). Primary endpoints: Sexual Desires Inventory-2 at 3 months and Patient Health Questionnaire at 3 months. Started May 2020; status: terminated.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT04002661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002661.